Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Safety and Efficacy of Personalized Immunotherapy Based on Neoantigens as Consolidation Therapy Following Standard Postoperative Adjuvant Treatment in Patients With Stage III Resectable Colorectal Cancer or Non-Small Cell Lung Cancer

NCT07504484 is registered in ClinicalTrials.gov with Ying Yuan, MD as lead sponsor.

NCT NCT07504484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07504484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Safety and Efficacy of Personalized Immunotherapy Based on Neoantigens as Consolidation Therapy Following Standard Postoperative Adjuvant Treatment in Patients With Stage III Resectable Colorectal Cancer or Non-Small Cell Lung Cancer
Lead sponsor
Ying Yuan, MD
Phase
Phase 1
Overall status
Completed
Start date
October 30, 2020
Completion date
December 31, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crc (colorectal cancer), non small lung cancer